China's National Medical Products Administration (NMPA) has accepted Legend Biotech Corporation's new drug application for its myeloma treatment therapy drug.
Legend Biotech announced the development in a January 2 press release.
“Meeting medical needs and serving patients around the world has always been the goal of Legend Biotech’s innovative research and development,” King Huang, Ph.D., Legend Biotech CEO, said in the release.
Legend biotech
| https://legendbiotech.com/about/our-story/
The drug called ciltacabatagene autoleucel, or cilta-cel, is used to help treat adults who have had three or more prior therapy to treat "relapsed or refractory multiple myeloma, according to the release.
In the release, Huang noted the drug has been approved for marketing in both the U.S. and Japan and has been authorized for "conditional marketing" in Europe. He added, "we look forward to the possibility of providing a new treatment option for appropriate patients with relapsed and refractory multiple myeloma in China.”
According to the company's website, Legend Biotech was founded in 2014 as an early-stage cell therapy company that has developed into a global company with locations in four countries including the U.S.